These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

338 related items for PubMed ID: 7514244

  • 1. Combination of hematopoietic growth factors containing IL-3 induce acute myeloid leukemia cell sensitization to cycle specific and cycle non-specific drugs.
    Tafuri A, Lemoli RM, Chen R, Gulati SC, Clarkson BD, Andreeff M.
    Leukemia; 1994 May; 8(5):749-57. PubMed ID: 7514244
    [Abstract] [Full Text] [Related]

  • 2. Enhanced chemosensitivity of clonogenic blasts from patients with acute myeloid leukemia by G-CSF, IL-3 or GM-CSF stimulation.
    te Boekhorst PA, Löwenberg B, Vlastuin M, Sonneveld P.
    Leukemia; 1993 Aug; 7(8):1191-8. PubMed ID: 7688839
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Hematopoietic growth factor stimulation and cytarabine cytotoxicity in vitro: effects in untreated and relapsed or primary refractory acute myeloid leukemia cells.
    te Boekhorst PA, Löwenberg B, Sonneveld P.
    Leukemia; 1994 Sep; 8(9):1480-6. PubMed ID: 7522289
    [Abstract] [Full Text] [Related]

  • 5. Proliferative response of human acute myeloid leukemia cells and normal marrow enriched progenitor cells to human recombinant growth factors IL-3, GM-CSF and G-CSF alone and in combination.
    Lemoli RM, Gulati SC, Strife A, Lambek C, Perez A, Clarkson BD.
    Leukemia; 1991 May; 5(5):386-91. PubMed ID: 1709711
    [Abstract] [Full Text] [Related]

  • 6. Granulocyte-macrophage colony-stimulating factor and interleukin-3 protect leukemic blast cells from ara-C toxicity.
    Koistinen P, Wang C, Curtis JE, McCulloch EA.
    Leukemia; 1991 Sep; 5(9):789-95. PubMed ID: 1719308
    [Abstract] [Full Text] [Related]

  • 7. [Enhanced sensitivity to cytosine arabinoside by combined stimulation of steel factor and GM-CSF in a factor-dependent leukemic cell line, MO7e--in terms of a possible clinical application to AML treatment].
    Gotoh A, Kawanishi Y, Kurosawa K, Miyazawa K, Ohtaka M, Aizawa S, Kimura Y, Yoshikawa O, Toyama K.
    Rinsho Ketsueki; 1993 Jul; 34(7):821-8. PubMed ID: 7689660
    [Abstract] [Full Text] [Related]

  • 8. OCI/AML-4 an acute myeloblastic leukemia cell line: regulation and response to cytosine arabinoside.
    Koistinen P, Wang C, Yang GS, Wang YF, Williams DE, Lyman SD, Minden MD, McCulloch EA.
    Leukemia; 1991 Aug; 5(8):704-11. PubMed ID: 1715961
    [Abstract] [Full Text] [Related]

  • 9. Enhanced chemosensitivity in acute myeloid leukemia by hematopoietic growth factors: a comparison of the MTT assay with a clonogenic assay.
    te Boekhorst PA, Löwenberg B, Sonneveld P.
    Leukemia; 1993 Oct; 7(10):1637-44. PubMed ID: 7692194
    [Abstract] [Full Text] [Related]

  • 10. Comparative effects of G-CSF, GM-CSF and IL-3 on cytosine arabinoside- and daunorubicin-mediated cytotoxicity of acute myeloid leukemia cells and normal myeloid progenitors.
    Waga K, Furusawa S, Nagashima S, Saito K, Shishido H.
    Int J Hematol; 1992 Aug; 56(1):17-27. PubMed ID: 1391803
    [Abstract] [Full Text] [Related]

  • 11. Effects of mast cell growth factor on acute myeloid leukemia cells in vitro: effects of combinations with other cytokines.
    Budel LM, Delwel R, van Buitenen C, Hoogerbrugge H, Löwenberg B.
    Leukemia; 1993 Mar; 7(3):426-34. PubMed ID: 7680401
    [Abstract] [Full Text] [Related]

  • 12. Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia.
    Cannistra SA, Groshek P, Griffin JD.
    Leukemia; 1989 May; 3(5):328-34. PubMed ID: 2654494
    [Abstract] [Full Text] [Related]

  • 13. Kinetic rationale for cytokine-induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro.
    Tafuri A, Andreeff M.
    Leukemia; 1990 Dec; 4(12):826-34. PubMed ID: 2243506
    [Abstract] [Full Text] [Related]

  • 14. In vitro response of blasts to IL-3, GM-CSF, and G-CSF is different for individual AML patients: factors that stimulate leukemic clonogenic cells also enhance Ara-C cytotoxicity.
    Van der Lely N, De Witte T, Wessels J, Raymakers R, Muus P, Preijers F.
    Ann Hematol; 1994 May; 68(5):225-32. PubMed ID: 7517190
    [Abstract] [Full Text] [Related]

  • 15. Establishment and characterization of two novel cytokine-responsive acute myeloid and monocytic leukemia cell lines, MUTZ-2 and MUTZ-3.
    Hu ZB, Ma W, Zaborski M, MacLeod R, Quentmeier H, Drexler HG.
    Leukemia; 1996 Jun; 10(6):1025-40. PubMed ID: 8667638
    [Abstract] [Full Text] [Related]

  • 16. Hemopoietin-1 activity of interleukin-1 (IL-1) on acute myeloid leukemia colony-forming cells (AML-CFU) in vitro: IL-1 induces production of tumor necrosis factor-alpha which synergizes with IL-3 or granulocyte-macrophage colony-stimulating factor.
    Delwel R, van Buitenen C, Salem M, Oosterom R, Touw I, Löwenberg B.
    Leukemia; 1990 Aug; 4(8):557-60. PubMed ID: 2201834
    [Abstract] [Full Text] [Related]

  • 17. Influence of schedule on regulated sensitivity of AML blasts to cytosine arabinoside.
    Yang GS, Minden MD, McCulloch EA.
    Leukemia; 1993 Jul; 7(7):1012-9. PubMed ID: 7686602
    [Abstract] [Full Text] [Related]

  • 18. Post-transcriptional regulation of bcl-2 in acute myeloblastic leukemia: significance for response to chemotherapy.
    Hu ZB, Minden MD, McCulloch EA.
    Leukemia; 1996 Mar; 10(3):410-6. PubMed ID: 8642855
    [Abstract] [Full Text] [Related]

  • 19. Effect of stem cell factor (c-kit ligand), granulocyte-macrophage colony stimulating factor and interleukin 3 on hematopoietic progenitors in human long-term bone marrow cultures.
    Lemoli RM, Gulati SC.
    Stem Cells; 1993 Sep; 11(5):435-44. PubMed ID: 7694721
    [Abstract] [Full Text] [Related]

  • 20. Prolonged exposure to cytosine arabinoside in the presence of hematopoietic growth factors preferentially kills leukemic versus normal clonogenic cells.
    Van Der Lely N, De Witte T, Muus P, Raymakers R, Preijers F, Haanen C.
    Exp Hematol; 1991 May; 19(4):267-72. PubMed ID: 2055291
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.